Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye.

• Published in: Acta Ophthalmologica
• Main Authors: Lorenzo-Soler, Laura, Praphanwittaya, Pitsiree, Olafsdottir, Olof Birna, Kristinsdottir, Iris Myrdal, Asgrimsdottir, Gudrun Marta, Loftsson, Thorsteinn, Stefansson, Einar
• Other Authors: 1Faculty of Medicine, University of Iceland, Reykjavík, Iceland. 2Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland. 3Department of Ophthalmology, Landspitali University Hospital, Reykjavík, Iceland. 4Oculis ehf., Reykjavík, Iceland.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2022
• Subjects: cediranib; cyclodextrins; drug delivery; in vivo; neovascularization; pharmacokinetics; topical administration; Iceland
• Online Access: http://hdl.handle.net/2336/622117; https://doi.org/10.1111/aos.15101

To access publisher's full text version of this article click on the hyperlink below Purpose: Tyrosine kinase inhibitors inhibit VEGF receptors. If delivered to the retina, they might inhibit oedema and neovascularization such as in age-related macular degeneration and diabetic retinopathy. The aim of this study was to formulate cediranib maleate, a potent VEGF inhibitor, as γ-cyclodextrin nanoparticle eye drops and measure the retinal delivery and overall ocular pharmacokinetics after a single-dose administration in rabbits. Methods: A novel formulation technology with 3% cediranib maleate as γ-cyclodextrin micro-suspension was prepared by autoclaving method. Suitable stabilizers were tested for heat-stable eye drops. The ophthalmic formulation was topically applied to one eye in rabbits. The pharmacokinetics in ocular tissues, tear film and blood samples were studied at 1, 3 and 6 hr after administration. Results: γ-cyclodextrin formed complex with cediranib maleate. The formation of γ-cyclodextrin nanoparticles occurred in concentrated complexing media. Combined stabilizers prevented the degradation of drug during the autoclaving process. Three hours after administration of the eye drops, treated eyes showed cediranib levels of 737 ± 460 nM (mean ± SD) in the retina and 10 ± 6 nM in the vitreous humour. Conclusions: Cediranib maleate in γ-cyclodextrin nanoparticles were stable to heat in presence of stabilizers. The drug as eye drops reached the retina in concentrations that are more than 100 times higher than the 0.4 nM IC50 value reported for the VEGF type-II receptor and thus, presumably, above therapeutic level. These results suggest that γ-cyclodextrin-based cediranib maleate eye drops deliver effective drug concentrations to the retina in rabbits after a single-dose administration. Keywords: cediranib; cyclodextrins; drug delivery; in vivo; neovascularization; pharmacokinetics; topical administration. Oculis ehf, Reykjavik, Iceland